Xiapex® gets recommendation to be made available on National Health Service in England

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces that for the first time people in England with the disabling hand condition Dupuytren’s disease will have access to Xiapex® (collagenase clostridium histolyticum (CCH)) injections, a pharmacological treatment for contracture of their fingers, on the National Health Service (NHS) after recommendation from The National Institute for Health and Care Excellence (NICE). “The availability of funding for Xiapex within NHS England is an important milestone for the Dupuytren’s community in the UK, as healthcare